CompletedPhase 2

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

255 participantsStarted 2004-09

Plain-language summary

This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma * At least one bone metastasis

Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)

Timeframe: Baseline and Week 13

NCT IDNCT00091832

SponsorAmgen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-11

Results submitted2010-12-09